Contributor Cindy H. Dubin interviews Serán and several other leading companies, on how they are using innovative technologies to improve bioavailability challenges.
Serán’s CEO, Dan Smithey, PhD, discusses the use of technology as the key enabler for overcoming molecules exhibiting low bioavailability. As molecules become more complex, so does the need to innovate and develop new technologies to resolve problems. “In addition to particle engineering, the development of solid dosage form is key to successfully improving bioavailability,” says Dr. Smithey.
Read on to learn more about Serán’s science-first, technology driven focus on turning complex molecules into medicines.